Breaking News

Tweet TWEET

Onyx Pharmaceuticals Announces Data Presentations at 49th American Society of Clinical Oncology Annual Meeting

Onyx Pharmaceuticals Announces Data Presentations at 49th American Society of 
Clinical Oncology Annual Meeting 
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 05/15/13 --  Onyx
Pharmaceuticals, Inc. (NASDAQ: ONXX) today announced the upcoming
presentations of data highlighting Nexavar(R) (sorafenib) tablets,
Kyprolis(R) (carfilzomib) for Injection, and Stivarga(R)
(regorafenib) tablets across a range of cancers. These presentations
will take place at the 49th American Society of Clinical Oncology
(ASCO) Annual Meeting, May 31 - June 4, 2013, in Chicago, IL.  
"The data being presented at ASCO add to the depth of our
understanding of how these medicines work across tumor types and
treatment settings," said Pablo Cagnoni, M.D., Executive Vice
President, Global Research & Development and Technical Operations at
Onyx Pharmaceuticals. "We are committed to exploring therapies in
difficult-to-treat cancers for patients who have limited treatment
options." 
Nexavar(R) (sorafenib) tablets 
Sorafenib in locally advanced or metastatic patients with radioactive
iodine-refractory differentiated thyroid cancer: The Phase 3 DECISION
trial  


 
--  Dr. Marcia Brose, University of Pennsylvania Health System, United
    States
--  Sunday, June 2, 2013
--  Oral Presentation: 3:20 - 3:35 p.m., N Hall B1
--  Plenary Session - Special Sessions, Core Sessions
--  Abstract # 4

  
Final analysis of GIDEON (Global Investigation of Therapeutic Decisions
in Hepatocellular Carcinoma [HCC] and of Its Treatment with Sorafenib
[Sor]) in > 3000 Sor-treated patients (pts): clinical findings in pts
with liver dysfunction 


 
--  Dr. Jorge Marrero, University of Michigan, United States
--  Sunday, June 2, 2013
--  Poster viewing: 8:00 - 11:45 a.m., S Hall A2
--  General poster session - Gastrointestinal (Noncolorectal) Cancer
--  Abstract # 4126

  
Kyprolis(R) (carfilzomib) for Injection  
Final results from the Phase 1b/2 study (PX-171-006) of carfilzomib,
lenalidomide, and low-dose dexamethasone (CRd) in patients with
relapsed or progressive multiple myeloma 


 
--  Dr. Michael Wang, MD Anderson Cancer Center, United States
--  Monday, June 3, 2013
--  Poster viewing: 1:15 - 5:15 p.m., E450b
--  Poster discussion: 4:45 - 5:45 p.m., E354b
--  Poster discussion session - Lymphoma and Plasma Cell Disorders, Poster
    #9
--  Abstract # 8529

  
Effect of CMP, carfilzomib (CFZ) plus melphalan-prednisone (MP), on
response rates in elderly patients (pts) with newly diagnosed
multiple myeloma (NDMM): Results of a Phase (Ph) 1/2 trial 


 
--  Dr. Cyrille Touzeau, University of Nantes, France
--  Monday, June 3, 2013
--  Oral Presentation: 9:15 - 9:30 a.m., E Arie Crown Theater
--  Oral abstract session - Myeloma
--  Abstract # 8513

  
Retrospective analysis of cardiovascular (CV) events following
compassionate use of carfilzomib (CFZ) in patients (Pts) with
relapsed and refractory multiple myeloma (RRMM) 


 
--  Dr. Shebli Atrash, University of Arkansas for Medical Sciences, United
    States
--  Sunday, June 2, 2013
--  Poster viewing: 8:00 - 11:45 a.m., S Hall A2
--  General poster session - Lymphoma and Plasma Cell Disorders
--  Abstract # 8595

  
Results of a Phase 1/2 study (NCT01365559) of carfilzomib (CFZ)
replacing bortezomib (BTZ) in BTZ-containing regimens for BTZ-treated
patients (pts) with relapsed and refractory multiple myeloma (MM) 


 
--  Dr. James R. Berenson, Institute for Myeloma & Bone Cancer
    Research, United States
--  Sunday, June 2, 2013
--  Poster viewing: 8:00 - 11:45 a.m., S Hall A2
--  General poster session - Lymphoma and Plasma Cell Disorders
--  Abstract # 8599

  
Results of a Phase 1 trial of the proteasome inhibitor carfilzomib in
patients with relapsed or refractory chronic lymphocytic leukemia
(CLL) and small lymphocytic leukemia (SLL) 


 
--  Dr. Jennifer Ann Woyach, Ohio State University, United States
--  Sunday, June 2, 2013
--  Poster viewing: 8:00 - 11:45 a.m., S Hall A2
--  General poster session - Leukemia, Myelodysplasia, and Transplantation
--  Abstract # 7077

  
Treatment outcome with the combination of carfilzomib, lenalidomide,
and low-dose dexamethasone (CRd) for newly diagnosed multiple myeloma
(NDMM) after extended follow-up 


 
--  Dr. Andrzej J. Jakubowiak, University of Chicago, United States
--  Monday, June 3, 2013
--  Poster viewing: 1:15 - 5:15 p.m., E450b
--  Poster discussion: 4:45 - 5:45 p.m., E354b
--  Poster discussion session - Lymphoma and Plasma Cell Disorders, Poster
    #23
--  Abstract # 8543

  
Stivarga(R) (regorafenib) tablets  
Mutational analysis of plasma DNA from patients (pts) in the Phase 3
GRID study of regorafenib (REG) vs placebo (PL) in tyrosine kinase
inhibitor (TKI)-refractory GIST: correlating genotype with clinical
outcomes 


 
--  Dr. George Demetri, Dana-Farber Cancer Institute, United States
--  Monday, June 3, 2013
--  Oral Presentation: 3:45 - 4:00 p.m., S100bc
--  Oral abstract session - Sarcoma
--  Abstract # 10503

  
Results from a Phase 3 trial (GRID) evaluating regorafenib (REG) in
metastatic gastrointestinal stromal tumour (GIST): subgroup analysis
of outcomes based on pretreatment characteristics 


 
--  Dr. Heikki Joensuu, Helsinki University Central Hospital, Finland
--  Saturday, June 1, 2013
--  Poster viewing: 1:15 - 5:00 p.m., S Hall A2
--  General poster session - Sarcoma
--  Abstract # 10551

  
Regorafenib (REG) in patients with hepatocellular carcinoma (HCC)
progressing following sorafenib: an ongoing randomized, double-blind,
Phase 3 trial 


 
--  Dr. Ann-Lii Cheng, National Taiwan University Hospital, Taipei
--  Sunday, June 2, 2013
--  Poster viewing: 8:00 - 11:45 a.m., S Hall A2
--  General poster session - Gastrointestinal (Noncolorectal) Cancer
--  Abstract # TPS4163 (Trials in Progress)

  
Time profile of adverse events (AEs) from regorafenib (REG) treatment
for metastatic colorectal cancer (mCRC) in the Phase 3 CORRECT study 


 
--  Dr. Axel Grothey, Mayo Clinic, United States
--  Sunday, June 2, 2013
--  Poster viewing: 8:00 - 11:45 a.m., S Hall A2
--  General poster session - Gastrointestinal (Colorectal) Cancer
--  Abstract # 3637

  
Regorafenib (REG) in progressive metastatic colorectal cancer (mCRC):
analysis of age subgroups in the Phase 3 CORRECT trial 


 
--  Dr. Eric van Cutsem, University Hospital Leuven in Gasthuisberg,
    Belgium
--  Sunday, June 2, 2013
--  Poster viewing: 8:00 - 11:45 a.m., S Hall A2
--  General poster session - Gastrointestinal (Colorectal) Cancer
--  Abstract # 3636

  
Analysis of plasma protein biomarkers from the CORRECT Phase 3 study of
regorafenib for metastatic colorectal cancer 


 
--  Dr. Heinz-Josef Lenz, USC Norris Comprehensive Cancer Center, United
    States
--  Tuesday, June 4, 2013
--  Poster viewing: 8:00 - 12:00 p.m., S405
--  Poster discussion: 11:30 - 12:30 p.m., S406
--  Poster discussion session - Gastrointestinal (Colorectal) Cancer,
    Poster #6
--  Abstract # 3514

  
About Nexavar(R) (sorafenib) Tablets 
Nexavar is approved in the U.S. for the treatment of patients with
unresectable hepatocellular carcinoma and for the treatment of
patients with advanced renal cell carcinoma. Nexavar is thought to
inhibit both the tumor cell and tumor vasculature. In preclinical
studies, Nexavar has been shown to inhibit multiple kinases thought
to be involved in both cell proliferation (growth) and angiogenesis
(blood supply) -- two important processes that enable cancer 
growth.
These kinases include Raf kinase, VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-B,
KIT, FLT-3 and RET. 
Nexavar is currently approved in more than 100 countries. Nexavar is
also being evaluated by Bayer and Onyx, international study groups,
government agencies and individual investigators in a range of
cancers. 
Important Safety Considerations For Nexavar(R) (sorafenib) Tablets 
Nexavar in combination with carboplatin and paclitaxel is
contraindicated in patients with squamous cell lung cancer. 
Cardiac ischemia and/or myocardial infarction may occur. Temporary or
permanent discontinuation of Nexavar should be considered in patients
who develop cardiac ischemia and/or myocardial infarction. 
An increased risk of bleeding may occur following Nexavar
administration. If bleeding necessitates medical intervention,
consider permanent discontinuation of Nexavar.  
Hypertension may occur early in the course of treatment. Monitor
blood pressure weekly during the first 6 weeks and periodically
thereafter and treat, if required. 
Hand-foot skin reaction and rash are common and management may
include topical therapies for symptomatic relief. In cases of any
severe or persistent adverse reactions, temporary treatment
interruption, dose modification, or permanent discontinuation of
Nexavar should be considered. Nexavar should be discontinued if
Stevens-Johnson Syndrome or toxic epidermal necrolysis are suspected
as these may be life threatening.  
Gastrointestinal perforation was an uncommon adverse reaction and has
been reported in less than 1% of patients taking Nexavar. Discontinue
Nexavar in the event of a gastrointestinal perforation. 
Patients taking concomitant warfarin should be monitored regularly
for changes in prothrombin time (PT), International Normalized Ratio
(INR) or clinical bleeding episodes. 
Temporary interruption of Nexavar therapy is recommended in patients
undergoing major surgical procedures.  
Nexavar in combination with gemcitabine/cisplatin is not recommended
in patients with squamous cell lung cancer. 
The safety and effectiveness of Nexavar has not been established in
patients with non-small cell lung cancer. 
Nexavar can prolong the QT/QTc interval and increase the risk for
ventricular arrhythmias. 
Avoid use in patients with congenital long QT syndrome and monitor
patients with congestive heart failure, bradyarrhythmias, drugs known
to prolong the QT interval, and electrolyte abnormalities. 
Drug-induced hepatitis with Nexavar may result in hepatic failure and
death. Liver function tests should be monitored regularly and in
cases of increased transaminases without alternative explanation
Nexavar should be discontinued.  
Nexavar may cause fetal harm when administered to a pregnant woman.
Women of childbearing potential should be advised to avoid becoming
pregnant while on Nexavar and female patients should also be advised
against breastfeeding while receiving Nexavar. 
Elevations in serum lipase and reductions in serum phosphate of
unknown etiology have been associated with Nexavar. 
Avoid concomitant use of strong CYP3A4 inducers, when possible,
because inducers can decrease the systemic exposure of Nexavar.
Nexavar exposure decreases when coadministered with oral neomycin.
Effects of other antibiotics on Nexavar pharmacokinetics have not
been studied. 
Most common adverse reactions reported for Nexavar-treated patients
vs. placebo-treated patients in unresectable HCC, respectively, were:
diarrhea (55% vs. 25%), fatigue (46% vs. 45%), abdominal pain (31%
vs. 26%), weight loss (30% vs. 10%), anorexia (29% vs. 18%), nausea
(24% vs. 20%), and hand-foot skin reaction (21% vs. 3%). Grade 3/4
adverse reactions were 45% vs. 32%. 
Most common adverse reactions reported for Nexavar-treated patients
vs. placebo-treated patients in advanced RCC, respectively, were:
diarrhea (43% vs. 13%), rash/desquamation (40% vs. 16%), fatigue (37%
vs. 28%), hand-foot skin reaction (30% vs. 7%), alopecia (27% vs.
3%), and nausea (23% vs. 19%). Grade 3/4 adverse reactions were 38%
vs. 28%. 
For information about Nexavar including U.S. Nexavar prescribing
information, visit www.nexavar-us.com or call 1.866.NEXAVAR
(1.866.639.2827). 
Indication and Important Safety Information for Kyprolis(R)
(carfilzomib) for Injection  
Kyprolis(TM) (carfilzomib) for Injection is indicated for the
treatment of patients with multiple myeloma who have received at
least 2 prior therapies including bortezomib and an immunomodulatory
agent and have demonstrated disease progression on or within 60 days
of completion of the last therapy. Approval is based on response
rate. Clinical benefit, such as improvement in survival or symptoms,
has not been verified. 
The safety of KYPROLIS was evaluated in clinical studies of 526
patients with relapsed and/or refractory multiple myeloma. 
Death due to cardiac arrest has occurred within a day of KYPROLIS
administration. New onset or worsening of pre-existing congestive
heart failure with decreased left ventricular function or myocardial
ischemia have occurred following administration of KYPROLIS. Cardiac
failure events (e.g., cardiac failure congestive, pulmonary edema,
ejection fraction decreased) were reported in 7% of patients. Monitor
for cardiac complications and manage promptly. Withhold KYPROLIS for
Grade 3 or 4 cardiac events until recovery and consider whether to
restart KYPROLIS based on a benefit/risk assessment. Patients with
New York Heart Association Class III and IV heart failure, myocardial
infarction in the preceding 6 months, and conduction abnormalities
uncontrolled by medications may be at greater risk for cardiac
complications.  
Pulmonary arterial hypertension (PAH) was reported in 2% of patients
treated with KYPROLIS and was Grade 3 or greater in less than 1% of
patients. Evaluate with cardiac imaging and/or other tests as
indicated. Withhold KYPROLIS for pulmonary hypertension until
resolved or returned to baseline and consider whether to restart
KYPROLIS based on a benefit/risk assessment. 
Dyspnea was reported in 35% of patients enrolled in clinical trials.
Grade 3 dyspnea occurred in 5%; no Grade 4 events, and 1 death (Grade
5) was reported. Monitor and manage dyspnea immediately; interrupt
KYPROLIS until symptoms have resolved or returned to baseline. 
Infusion reactions were characterized by a spectrum of systemic
symptoms, including fever, chills, arthralgia, myalgia, facial
flushing, facial edema, vomiting, weakness, shortness of breath,
hypotension, syncope, chest tightness, or angina. These reactions can
occur immediately following infusion or up to 24 hours after
administration of KYPROLIS. Administer dexamethasone prior to
KYPROLIS to reduce the incidence and severity of reactions. Inform
patients of the risk and symptoms, and to contact physician if
symptoms of an infusion reaction occur. 
Tumor lysis syndrome (TLS) occurred following KYPROLIS administration
in < 1% of patients. Patients with multiple myeloma and a high tumor
burden should be considered to be at greater risk for TLS. Prior to
receiving KYPROLIS, ensure that patients are well hydrated. Monitor
for evidence of TLS during treatment, and manage promptly. Interrupt
KYPROLIS until TLS is resolved. 
KYPROLIS causes thrombocytopenia with platelet nadirs occurring
around Day 8 of each 28-day cycle and recovery to baseline by the
start of the next 28-day cycle. In patients with multiple myeloma,
36% of patients experienced thrombocytopenia, including Grade 4 in
10%. Thrombocytopenia following KYPROLIS administration resulted in a
dose reduction in 1% of patients and discontinuation of treatment
with KYPROLIS in < 1% of patients. Monitor platelet counts frequently
during treatment with KYPROLIS. Reduce or interrupt dose as
clinically indicated. 
Cases of hepatic failure, including fatal cases, have been reported (
< 1%). KYPROLIS can cause elevations of serum transaminases and
bilirubin. Withhold KYPROLIS in patients experiencing Grade 3 or
greater elevations of transaminases, bilirubin, or other liver enzyme
abnormalities until resolved or returned to baseline. After
resolution, consider if restarting KYPROLIS is appropriate. Monitor
liver enzymes frequently. 
KYPROLIS can cause fetal harm when administered to a pregnant woman
based on its mechanism of action and findings in animals. There are
no adequate and well-controlled studies in pregnant women using
KYPROLIS. Carfilzomib caused embryo-fetal toxicity in pregnant
rabbits at doses that were lower than in patients receiving the
recommended dose. Females of reproductive potential should be advised
to avoid becoming pregnant while being treated with KYPROLIS. 
Serious adverse reactions were reported in 45% of patients. The most
common serious adverse reactions were pneumonia (10%), acute renal
failure (4%), pyrexia (3%), and congestive heart failure (3%).
Adverse reactions leading to discontinuation of KYPROLIS occurred in
15% of patients and included congestive heart failure (2%), cardiac
arrest, dyspnea, increased blood creatinine, and acute renal failure
(1% each). 
The most common adverse reactions (incidence &#8805; 30%) were
fatigue (56%), anemia (47%), nausea (45%), thrombocytopenia (36%),
dyspnea (35%), diarrhea (33%), and pyrexia (30%). 
Since dialysis clearance of KYPROLIS concentrations has not been
studied, the drug should be administered after the dialysis
procedure. 
Full prescribing information is available at http://www.kyprolis.com. 
About Stivarga(R) (regorafenib) Tablets
 In the United States,
Stivarga is indicated for the treatment of patients with mCRC who
have been previously treated with fluoropyrimidine-, oxaliplatin- and
irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS
wild type, an anti-EGFR therapy. It is also indicated for the
treatment of patients with locally advanced, unresectable or
metastatic gastrointestinal stromal tumor (GIST) who have been
previously treated with imatinib mesylate and sunitinib malate. 
Stivarga is an inhibitor of multiple kinases involved in normal
cellular functions and in pathologic processes such as oncogenesis,
tumor angiogenesis, and maintenance of the tumor microenvironment. 
For full prescribing information, including BOXED WARNING, visit
www.stivarga-us.com. 
Important Safety Information For Stivarga(R) (regorafenib) Tablets 
WARNING: HEPATOTOXICITY  


 
--  Severe and sometimes fatal hepatotoxicity has been observed in
    clinical trials.
--  Monitor hepatic function prior to and during treatment.
--  Interrupt and then reduce or discontinue Stivarga for hepatotoxicity
    as manifested by elevated liver function tests or hepatocellular
    necrosis, depending upon severity and persistence.

  
Severe drug-induced liver injury with fatal outcome occurred in 0.3% of
1200 Stivarga-treated patients across all clinical trials. In
metastatic colorectal cancer (mCRC), fatal hepatic failure occurred
in 1.6% of patients in the Stivarga arm and in 0.4% of patients in
the placebo arm; all the patients with hepatic failure had metastatic
disease in the liver. In gastrointestinal stromal tumor (GIST), fatal
hepatic failure occurred in 0.8% of patients in the Stivarga arm.  
Obtain liver function tests (ALT, AST, and bilirubin) before
initiation of Stivarga and monitor at least every 2 weeks during the
first 2 months of treatment. Thereafter, monitor monthly or more
frequently as clinically indicated. Monitor liver function tests
weekly in patients experiencing elevated liver function tests until
improvement to less than 3 times the upper limit of normal (ULN) or
baseline values. Temporarily hold and then reduce or permanently
discontinue Stivarga, depending on the severity and persistence of
hepatotoxicity as manifested by elevated liver function tests or
hepatocellular necrosis. 
Stivarga caused an increased incidence of hemorrhage. The overall
incidence (Grades 1-5) was 21% and 11% with Stivarga vs 8% and 3%
with placebo in mCRC and GIST patients, respectively. Fatal
hemorrhage occurred in 4 of 632 (0.6%) Stivarga-treated patients and
involved the respiratory, gastrointestinal, or genitourinary tracts.
Permanently discontinue Stivarga in patients with severe or
life-threatening hemorrhage and monitor INR levels more frequently in
patients receiving warfarin. 
Stivarga caused an increased incidence of hand-foot skin reaction
(HFSR) (also known as palmar-plantar erythrodysesthesia [PPE]) and
severe rash, frequently requiring dose modification. The overall
incidence was 45% and 67% with Stivarga vs 7% and 12% with placebo in
mCRC and GIST patients, respectively. Incidence of Grade 3 HFSR (17%
vs 0% in mCRC and 22% vs 0% in GIST), Grade 3 rash (6% vs < 1% in
mCRC and 7% vs 0% in GIST), serious adverse reactions of erythema
multiforme (0.2% vs 0% in mCRC), and Stevens-Johnson syndrome (0.2%
vs 0% in mCRC) was higher in Stivarga-treated patients. Toxic
epidermal necrolysis occurred in 0.17% of 1200 Stivarga-treated
patients across all clinical trials. Withhold Stivarga, reduce the
dose, or permanently discontinue depending on the severity and
persistence of dermatologic toxicity. 
Stivarga caused an increased incidence of hypertension (30% vs 8% in
mCRC and 59% vs 27% in GIST with Stivarga vs placebo, respectively).
Hypertensive crisis occurred in 0.25% of 1200 Stivarga-treated
patients across all clinical trials. Do not initiate Stivarga until
blood pressure is adequately controlled. Monitor blood pressure
weekly for the first 6 weeks of treatment and then every cycle, or
more frequently, as clinically indicated. Temporarily or permanently
withhold Stivarga for severe or uncontrolled hypertension. 
Stivarga increased the incidence of myocardial ischemia and
infarction in mCRC (1.2% with Stivarga vs 0.4% with placebo).
Withhold Stivarga in patients who develop new or acute cardiac
ischemia or infarction, and resume only after resolution of acute
cardiac ischemic events if the potential benefits outweigh the risks
of further cardiac ischemia. 
Reversible Posterior Leukoencephalopathy Syndrome (RPLS) occurred in
1 of 1200 Stivarga-treated patients across all clinical trials.
Perform an evaluation for RPLS in any patient presenting with
seizures, headache, visual disturbances, confusion, or altered mental
function. Confirm the diagnosis of RPLS with MRI and discontinue
Stivarga in patients who develop RPLS. 
Gastrointestinal perforation or fistula occurred in 0.6% of 1200
patients treated with Stivarga across clinical trials. In GIST, 2.1%
(4/188) of Stivarga-treated patients developed gastrointestinal
fistula or perforation: of these, 2 cases of gastrointestinal
perforation were fatal. Permanently discontinue Stivarga in patients
who develop gastrointestinal perforation or fistula. 
Treatment with Stivarga should be stopped at least 2 weeks prior to
scheduled surgery. Resuming treatment after surgery should be based
on clinical judgment of adequate wound healing. Stivarga should be
discontinued in patients with wound dehiscence. 
Stivarga can cause fetal harm when administered to a pregnant woman.
Use effective contraception during treatment and up to 2 months after
completion of therapy. If this drug is used during pregnancy, or if
the patient becomes pregnant while taking this drug, the patient
should be apprised of the potential hazard to the fetus. 
Because many drugs are excreted in huma
n milk and because of the
potential for serious adverse reactions in nursing infants from
Stivarga, a decision should be made whether to discontinue nursing or
discontinue the drug, taking into account the importance of the drug
to the mother. 
The most frequently observed adverse drug reactions ( &#8805; 30%) in
Stivarga-treated patients vs placebo-treated patients in mCRC,
respectively, were: asthenia/fatigue (64% vs 46%), decreased appetite
and food intake (47% vs 28%), HFSR/PPE (45% vs 7%), diarrhea (43% vs
17%), mucositis (33% vs 5%), weight loss (32% vs 10%), infection (31%
vs 17%), hypertension (30% vs 8%), and dysphonia (30% vs 6%). 
The most frequently observed adverse drug reactions ( &#8805; 30%) in
Stivarga-treated patients vs placebo-treated patients in GIST,
respectively, were: HFSR/PPE (67% vs 15%), hypertension (59% vs 27%),
asthenia/fatigue (52% vs 39%), diarrhea (47% vs 9%), mucositis (40%
vs 8%), dysphonia (39% vs 9%), infection (32% vs 5%), decreased
appetite and food intake (31% vs 21%), and rash (30% vs 3%). 
For full prescribing information, including BOXED WARNING, visit
www.stivarga-us.com. 
About Onyx Pharmaceuticals, Inc. 
Based in South San Francisco, California, Onyx Pharmaceuticals, Inc.
is a global biopharmaceutical company engaged in the development and
commercialization of innovative therapies for improving the lives of
people with cancer. The company is focused on developing novel
medicines that target key molecular pathways. For more information
about Onyx, visit the company's website at www.onyx.com. Onyx
Pharmaceuticals is on Twitter. Sign up to follow our Twitter feed
@OnyxPharm at http://twitter.com/OnyxPharm.  
Forward-Looking Statements 
This news release contains "forward-looking statements" of Onyx
within the meaning of the federal securities laws. These
forward-looking statements include without limitation, statements
regarding the progress and results of the clinical development,
safety, regulatory processes, commercialization efforts or commercial
potential of Nexavar(R) (sorafenib) tablets, Kyprolis(R)
(carfilzomib) for Injection and Stivarga(R) (regorafenib) tablets.
These statements are subject to risks and uncertainties that could
cause actual results and events to differ materially from those
anticipated, including risks related to the development and
commercialization of pharmaceutical products. Any statements
contained in this press release that are not statements of historical
fact may be deemed to be forward-looking statements. Reference should
be made to Onyx's Quarterly Report on Form 10-Q for the quarterly
period ended March 31, 2013, filed with the Securities and Exchange
Commission under the heading "Risk Factors" for a more detailed
description of such factors. Readers are cautioned not to place undue
reliance on these forward-looking statements that speak only as of
the date of this release. Onyx undertakes no obligation to update
publicly any forward-looking statements to reflect new information,
events, or circumstances after the date of this release except as
required by law. 
Contacts: 
Investors 
Amy Figueroa 
Senior Director, Investor Relations 
(650) 266-2398  
Media
Lori Melancon
Senior Director, Corporate Communications
(650) 266-2394 
 
 
Press spacebar to pause and continue. Press esc to stop.